Key Highlights

  • Shares closed up 5.12% at $37.84, trading near a 52-week high.
  • The company announced plans to close three Multiomics lab sites in North America.
  • The closures are expected to result in $11 million to $13 million in charges and about $11 million in annualized savings.
  • The company continues to work through the August resignation of former CEO John Marotta and related law firm investigations.
  • The stock trades at a price-to-sales ratio of about 2.6 times, below a 4.4 times industry average, according to one valuation commentary service.

Shares Gain Despite Ongoing Governance Overhang

Azenta (NASDAQ:AZTA) shares closed higher, rebounding alongside a broadly firmer healthcare sector even as the company continues to navigate a governance overhang and an ongoing restructuring. Azenta is a global life sciences company that provides solutions for the storage, management, and analysis of biological and chemical samples, operating through its Sample Management Solutions and Multiomics segments and serving pharmaceutical, biotechnology, and academic customers worldwide.

The company is still working through the fallout from the August resignation of former chief executive officer John Marotta, which has been followed by law firm investigations into potential securities claims.

Lab Closures Aim to Streamline Multiomics Operations

This week, Azenta also announced plans to close three Multiomics lab sites in North America, a move expected to generate $11 million to $13 million in one-time charges against about $11 million in annualized savings. The restructuring follows a roughly 8% drop in the stock on October 6, when the closures were first disclosed.

Valuation Seen as Undervalued Despite Recent Weakness

One valuation commentary service has argued the shares look undervalued on a sales basis, trading at roughly 2.6 times sales versus a 4.4 times industry average, even though the stock remains down about 64% over the past five years. Today's gain came as healthcare broadly outperformed, with the sector ETF up about 1.6% amid a defensive rotation as technology stocks softened and Treasury yields stayed elevated.

What Comes Next for Azenta's Restructuring Story

Investors are likely to watch for further detail on the Leadership search to replace the departed CEO, updates on the law firm investigations, and confirmation that the Multiomics lab closures are delivering the targeted cost savings in coming quarters.